NASDAQ: GPCR Structure Therapeutics Inc. 8-K

Structure Therapeutics hires Matthew Lang as COO and General Counsel ahead of Phase 3

Filed April 15, 2026 · Period ending April 15, 2026 · ~1 min read

Key Changes

medium

Matthew Lang appointed Chief Operating Officer and General Counsel effective April 15, 2026, consolidating operational and legal leadership as the company prepares to advance obesity drug aleniglipron into Phase 3 trials.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
medium

Lang brings experience guiding Metsera through its up to $10 billion Pfizer acquisition and leading two Myovant drugs through Phase 3 development to global approval and commercialization, relevant experience for Structure's late-stage plans.

Exhibit 99.1 view on EDGAR →
low

Compensation includes $560,000 base salary, 40% target bonus, stock options for 74,592 ADSs, time-based RSUs for 61,538 ADSs, and performance RSUs for 15,385 ADSs at target with milestones through June 2029.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
medium

Half of Lang's performance equity vests based on an undisclosed milestone due by June 2029, with potential payout ranging from 75% to 125% of target depending on achievement timing within the performance period.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →

Summary

Structure Therapeutics hired Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026, consolidating two executive functions under one leader as the clinical-stage biotech prepares to move its lead obesity candidate, aleniglipron, into Phase 3 trials.

Lang's background is directly relevant to this transition: he most recently served as Chief Legal Officer at Metsera through its up to $10 billion acquisition by Pfizer, and before that held executive roles at Myovant Sciences where he helped guide two drugs through Phase 3 development to global approval and commercialization.

The CEO explicitly framed the hire as critical for the company's Phase 3 plans and building a world-class leadership team. Lang's compensation package includes performance-based equity tied to three undisclosed milestones extending through June 2029, with half of the performance RSUs vesting based on that final milestone. The structure suggests the company has defined multi-year operational objectives aligned with late-stage development timelines. For retail holders, this is a standard executive hire at an appropriate stage—Structure is staffing up for Phase 3 execution with someone who has done it before. The dual COO/General Counsel role is somewhat unusual but reflects the company's current size and priorities.

Section-by-Section Diff

Event · Exhibit 99.1

~1,200 words View exhibit on EDGAR ↗

3 Added

Added COO and General Counsel appointment medium

Added in current filing · view on EDGAR →

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development.

Structure Therapeutics hired Matthew Lang as Chief Operating Officer and General Counsel. Lang brings over fifteen years of executive leadership experience in biopharmaceutical companies, with expertise in legal, corporate strategy, compliance, risk management, and business development. This dual-role appointment consolidates operational and legal leadership as the company prepares to advance its lead obesity drug candidate, aleniglipron, into Phase 3 clinical trials.

Added Executive background and experience medium

Added in current filing · view on EDGAR →

Mr. Lang most recently served as Chief Legal Officer and Secretary at Metsera, Inc., helping to guide the company through its up to $10 billion acquisition by Pfizer. Prior to Metsera, Mr. Lang served as Chief Business and Legal Officer at Lyell Immunopharma, Inc., and held several executive officer positions at Myovant Sciences, where he helped lead the company through Phase 3 clinical development, global approval and commercialization of Myfembree® and Orgovyx®. Mr. Lang also served as the Managing Director and General Manager of Myovant’s European operations in Basel Switzerland where he was responsible for all aspects of Myovant’s ex-US business operations.

Lang's recent experience includes serving as Chief Legal Officer at Metsera through its up to $10 billion acquisition by Pfizer, and holding executive roles at Lyell Immunopharma and Myovant Sciences. At Myovant, he helped lead two drugs through Phase 3 development to global approval and commercialization, and managed the company's European operations. This background in late-stage development, commercialization, and strategic transactions aligns with Structure's upcoming Phase 3 plans for aleniglipron.

Added Strategic timing and company stage medium

Added in current filing · view on EDGAR →

“Matt is a proven leader with a strong track record of guiding organizations through growth and transformation,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “His experience across global operations, strategic transactions, and commercialization will be critical as we move aleniglipron into Phase 3 and continue to build a world-class leadership team.”

The CEO emphasized that Lang's appointment comes as the company prepares to advance aleniglipron into Phase 3 trials. The timing suggests Structure is building out its leadership team in anticipation of late-stage development and potential commercialization activities. Lang's experience with global operations, strategic transactions, and commercialization is positioned as critical for this next phase of company growth.

Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation

~1,000 words

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.

3 Added

Added COO and General Counsel appointment medium

Added in current filing · verify on EDGAR →

Matthew Lang was appointed as Structure Therapeutics, Inc.’s (the “Company”) Chief Operating Officer and General Counsel, effective April 15, 2026.

Matthew Lang joined as COO and General Counsel on April 15, 2026. He previously served as Chief Legal Officer at Metsera (April 2025-February 2026) and held dual Chief Business Officer and Chief Legal Officer roles at Lyell Immunopharma (July 2023-April 2025). Before that, he was Chief Administrative and Legal Officer at Myovant Sciences and held leadership positions at Gilead Sciences.

Show 2 minor / wording changes

Added Base compensation low

Added in current filing · verify on EDGAR →

Mr. Lang will receive a base salary of $560,000 per year and be eligible for an annual discretionary bonus with a target amount of 40% of his base salary based on the achievement of certain corporate and/or individual objectives and milestones that are determined by the Board of Directors of the Company, with no pro-ration of any annual discretionary bonus payout for 2026.

Lang's compensation includes a $560,000 annual base salary and a target annual bonus of 40% of base salary ($224,000 target). The 2026 bonus will not be prorated despite his mid-year start date, meaning he is eligible for the full target amount based on achievement of Board-determined objectives.

Added Equity grants low

Added in current filing · verify on EDGAR →

Mr. Lang will be granted (i) an option to purchase 223,776 ordinary shares (representing 74,592 American Depositary Shares (“ADSs”)), (ii) a time-based restricted share unit award (the “RSUs”) in respect of 184,614 ordinary shares (representing 61,538 ADSs) and (iii) a performance-based restricted share unit award (the “PSUs”) in respect of 46,155 ordinary shares (representing 15,385 ADSs) at target levels.

Lang received three equity awards: stock options for 74,592 ADSs, time-based RSUs for 61,538 ADSs, and performance-based PSUs for 15,385 ADSs at target. The options vest over four years (25% after year one, then monthly). The RSUs vest 25% annually over four years. The PSUs vest based on three milestones with performance periods ending December 2027, September 2028, and June 2029, with potential payouts ranging from 75% to 125% of target depending on achievement timing.